Two new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended two medicines for approval at its June 2023 meeting.
The committee recommended granting a marketing authorisation for Aquipta (atogepant), intended for the prophylaxis of migraine in adults who have at least four migraine days per month. It is estimated that approximately 15% of the EU population suffers from migraine, a type of headache characterised by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.
Jesduvroq (daprodustat) received a positive opinion from the CHMP for the treatment of adult patients with anaemia associated with chronic kidney disease, a condition in which the kidneys are damaged and cannot filter the blood as well as they should…
